Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ISRG's Cash to Debt is ranked higher than
90% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ISRG: No Debt )
ISRG' s 10-Year Cash to Debt Range
Min: 12.85   Max: No Debt
Current: No Debt

Equity to Asset 0.85
ISRG's Equity to Asset is ranked higher than
89% of the 447 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ISRG: 0.85 )
ISRG' s 10-Year Equity to Asset Range
Min: 0.7   Max: 0.9
Current: 0.85

0.7
0.9
Interest Coverage No Debt
ISRG's Interest Coverage is ranked higher than
85% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. ISRG: No Debt )
ISRG' s 10-Year Interest Coverage Range
Min: 232.79   Max: 9999.99
Current: No Debt

232.79
9999.99
F-Score: 5
Z-Score: 21.54
M-Score: -2.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.97
ISRG's Operating margin (%) is ranked higher than
97% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. ISRG: 26.97 )
ISRG' s 10-Year Operating margin (%) Range
Min: -191.81   Max: 40.3
Current: 26.97

-191.81
40.3
Net-margin (%) 20.83
ISRG's Net-margin (%) is ranked higher than
96% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. ISRG: 20.83 )
ISRG' s 10-Year Net-margin (%) Range
Min: -180.68   Max: 41.41
Current: 20.83

-180.68
41.41
ROE (%) 13.42
ISRG's ROE (%) is ranked higher than
88% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. ISRG: 13.42 )
ISRG' s 10-Year ROE (%) Range
Min: -86.04   Max: 24.85
Current: 13.42

-86.04
24.85
ROA (%) 11.59
ISRG's ROA (%) is ranked higher than
92% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. ISRG: 11.59 )
ISRG' s 10-Year ROA (%) Range
Min: -58.81   Max: 22
Current: 11.59

-58.81
22
ROC (Joel Greenblatt) (%) 134.87
ISRG's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. ISRG: 134.87 )
ISRG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1443.26   Max: 245.9
Current: 134.87

-1443.26
245.9
Revenue Growth (%) 17.20
ISRG's Revenue Growth (%) is ranked higher than
91% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. ISRG: 17.20 )
ISRG' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 57.1
Current: 17.2

0
57.1
EBITDA Growth (%) 15.80
ISRG's EBITDA Growth (%) is ranked higher than
87% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. ISRG: 15.80 )
ISRG' s 10-Year EBITDA Growth (%) Range
Min: -62.7   Max: 321.3
Current: 15.8

-62.7
321.3
EPS Growth (%) 20.90
ISRG's EPS Growth (%) is ranked higher than
86% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ISRG: 20.90 )
ISRG' s 10-Year EPS Growth (%) Range
Min: -61.5   Max: 76.8
Current: 20.9

-61.5
76.8
» ISRG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ISRG Guru Trades in Q4 2013

RS Investment Management 301,632 sh (New)
Lee Ainslie 91,500 sh (New)
Louis Moore Bacon 15,000 sh (New)
Frank Sands 2,137,990 sh (+30.37%)
Paul Tudor Jones 1,222 sh (+22.2%)
Robert Olstein 13,000 sh (+18.18%)
Ray Dalio 39,898 sh (+11.45%)
John Burbank Sold Out
Andreas Halvorsen Sold Out
Jeremy Grantham 32,071 sh (-7.81%)
Ron Baron 60,000 sh (-36.88%)
Jim Simons 208,720 sh (-54.18%)
Joel Greenblatt 11,086 sh (-56.94%)
Steven Cohen 1,600 sh (-99.57%)
» More
Q1 2014

ISRG Guru Trades in Q1 2014

Steven Cohen 29,761 sh (+1760.06%)
Jeremy Grantham 52,332 sh (+63.18%)
Frank Sands 2,192,223 sh (+2.54%)
Louis Moore Bacon Sold Out
Ron Baron Sold Out
Paul Tudor Jones Sold Out
Lee Ainslie Sold Out
Robert Olstein 12,000 sh (-7.69%)
Joel Greenblatt 8,501 sh (-23.32%)
RS Investment Management 227,469 sh (-24.59%)
Jim Simons 108,500 sh (-48.02%)
Ray Dalio 3,080 sh (-92.28%)
» More
Q2 2014

ISRG Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 161,350 sh (New)
George Soros 45,100 sh (New)
Vanguard Health Care Fund 414,400 sh (New)
Joel Greenblatt 15,023 sh (+76.72%)
Robert Olstein 17,000 sh (+41.67%)
Jeremy Grantham 67,006 sh (+28.04%)
RS Investment Management 268,929 sh (+18.23%)
Ray Dalio Sold Out
Frank Sands 1,939,418 sh (-11.53%)
Jim Simons 63,400 sh (-41.57%)
» More
Q3 2014

ISRG Guru Trades in Q3 2014

John Hussman 5,000 sh (New)
John Burbank 1,219 sh (New)
Ray Dalio 1,923 sh (New)
Steven Cohen 61,900 sh (New)
Dodge & Cox 500 sh (New)
Jeremy Grantham 170,743 sh (+154.82%)
Vanguard Health Care Fund 414,400 sh (unchged)
George Soros Sold Out
Frank Sands Sold Out
Manning & Napier Advisors, Inc 158,050 sh (-2.05%)
Robert Olstein 15,000 sh (-11.76%)
RS Investment Management 210,219 sh (-21.83%)
Jim Simons 45,070 sh (-28.91%)
Joel Greenblatt 10,420 sh (-30.64%)
» More
» Details

Insider Trades

Latest Guru Trades with ISRG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Frank Sands 2014-09-30 Sold Out 2%$380.26 - $480.73 $ 523.5117%0
John Hussman 2014-09-30 New Buy0.2%$380.26 - $480.73 $ 523.5117%5000
George Soros 2014-09-30 Sold Out 0.14%$380.26 - $480.73 $ 523.5117%0
Robert Olstein 2014-09-30 Reduce -11.76%0.11%$380.26 - $480.73 $ 523.5117%15000
Joel Greenblatt 2014-09-30 Reduce -30.64%0.02%$380.26 - $480.73 $ 523.5117%10420
Ray Dalio 2014-09-30 New Buy0.01%$380.26 - $480.73 $ 523.5117%1923
John Burbank 2014-09-30 New Buy0.01%$380.26 - $480.73 $ 523.5117%1219
Dodge & Cox 2014-09-30 New Buy$380.26 - $480.73 $ 523.5117%500
Vanguard Health Care Fund 2014-06-30 New Buy0.45%$352.35 - $540.63 $ 523.5132%414400
Frank Sands 2014-06-30 Reduce -11.53%0.29%$352.35 - $540.63 $ 523.5132%1939418
Robert Olstein 2014-06-30 Add 41.67%0.28%$352.35 - $540.63 $ 523.5132%17000
George Soros 2014-06-30 New Buy0.14%$352.35 - $540.63 $ 523.5132%45100
Joel Greenblatt 2014-06-30 Add 76.72%0.03%$352.35 - $540.63 $ 523.5132%15023
Ray Dalio 2014-06-30 Sold Out 0.01%$352.35 - $540.63 $ 523.5132%0
Lee Ainslie 2014-03-31 Sold Out 0.45%$370.94 - $453.84 $ 523.5124%0
Ray Dalio 2014-03-31 Reduce -92.28%0.11%$370.94 - $453.84 $ 523.5124%3080
Ron Baron 2014-03-31 Sold Out 0.1%$370.94 - $453.84 $ 523.5124%0
Joel Greenblatt 2014-03-31 Reduce -23.32%0.02%$370.94 - $453.84 $ 523.5124%8501
John Burbank 2013-12-31 Sold Out 0.89%$355.93 - $401.68 $ 523.5138%0
Frank Sands 2013-12-31 Add 30.37%0.49%$355.93 - $401.68 $ 523.5138%2137990
Lee Ainslie 2013-12-31 New Buy0.45%$355.93 - $401.68 $ 523.5138%91500
Andreas Halvorsen 2013-12-31 Sold Out 0.44%$355.93 - $401.68 $ 523.5138%0
Joel Greenblatt 2013-12-31 Reduce -56.94%0.18%$355.93 - $401.68 $ 523.5138%11086
Robert Olstein 2013-12-31 Add 18.18%0.11%$355.93 - $401.68 $ 523.5138%13000
Ron Baron 2013-12-31 Reduce -36.88%0.06%$355.93 - $401.68 $ 523.5138%60000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Intuitive Surgical Inc

Baron Funds Comments on Intuitive Surgical - May 05, 2014

We sold out of the last of long-term holding Intuitive Surgical, Inc. (ISRG) Intuitive was one of the great investments in the Fund's history, but we let go of the last remnants of our position as the stock rebounded, and we felt uncertain about the device's utility in some of its new general surgery applications. Intuitive also has a $16 billion market cap on sale (it was $350 million on purchase!), and we need to be cognizant of market cap in our portfolio construction.





From Baron Funds' first quarter 2014 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Intuitive Surgical Inc. - Nov 21, 2013

Intuitive Surgical, Inc. (ISRG), which sells the da Vinci robotic surgical systems, fell 25.7% in the quarter when results fell short of expectations as growth in procedures slowed and unit placements declined. Hospital admissions have been weak and negative publicity affected the amount of procedures performed. We reduced our position in the stock by half this year, but now believe the stock is oversold and too cheap.

From Ron Baron’s Baron Funds third quarter 2013 report.


Check out Ron Baron latest stock trades

Baron Funds Comments on Intuitive Surgical Inc. - Nov 06, 2013

Intuitive Surgical, Inc. (ISRG) sells the 'da Vinci' robotic surgical system. The company's recent results fell short of expectations because of a slowdown in domestic benign gynecological procedures using da Vinci devices. This, in turn, led to slower than expected overall procedure growth and systems sales; management lowered its full year 2013 guidance as a result. After recognizing significant profits, we trimmed our position in the stock earlier this year because of concerns about the impact that increased focus on cost containment in the healthcare system might have on the company's long- term growth prospects. We continue to own a small position in the Fund.

From Ron Baron's Baron Funds third quarter 2013 report.


Check out Ron Baron latest stock trades

Top Ranked Articles about Intuitive Surgical Inc

Manning & Napier's Top 5 Second Quarter Stock Buys
Manning & Napier Advisers Inc., a New York investment management firm with $54.1 billion in assets under management, had a portfolio valued at $25.5 billion at June 30. Managers purchased 52 new positions in the second quarter, the top five largest of which are: Priceline Group Inc. (PCLN), Intuitive Surgical Inc. (ISRG), ProShares Short 20+ Year Treasury ETF (TBF), ARRIS Group Inc. (ARRS) and Republic Airways Holdings Inc. (RJET). Read more...
Baron Funds Comments on Intuitive Surgical
We sold out of the last of long-term holding Intuitive Surgical, Inc. (ISRG) Intuitive was one of the great investments in the Fund's history, but we let go of the last remnants of our position as the stock rebounded, and we felt uncertain about the device's utility in some of its new general surgery applications. Intuitive also has a $16 billion market cap on sale (it was $350 million on purchase!), and we need to be cognizant of market cap in our portfolio construction. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 45.40
ISRG's P/E(ttm) is ranked higher than
78% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 85.90 vs. ISRG: 45.40 )
ISRG' s 10-Year P/E(ttm) Range
Min: 17.79   Max: 207.43
Current: 45.4

17.79
207.43
P/B 6.10
ISRG's P/B is ranked higher than
60% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. ISRG: 6.10 )
ISRG' s 10-Year P/B Range
Min: 1.84   Max: 15.72
Current: 6.1

1.84
15.72
P/S 9.40
ISRG's P/S is ranked higher than
58% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. ISRG: 9.40 )
ISRG' s 10-Year P/S Range
Min: 4.16   Max: 24.31
Current: 9.4

4.16
24.31
PFCF 31.70
ISRG's PFCF is ranked higher than
87% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ISRG: 31.70 )
ISRG' s 10-Year PFCF Range
Min: 18.4   Max: 506.71
Current: 31.7

18.4
506.71
EV-to-EBIT 31.45
ISRG's EV-to-EBIT is ranked higher than
78% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. ISRG: 31.45 )
ISRG' s 10-Year EV-to-EBIT Range
Min: -164.8   Max: 244.8
Current: 31.45

-164.8
244.8
PEG 2.04
ISRG's PEG is ranked higher than
94% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ISRG: 2.04 )
ISRG' s 10-Year PEG Range
Min: 0.17   Max: 3.65
Current: 2.04

0.17
3.65
Shiller P/E 44.00
ISRG's Shiller P/E is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ISRG: 44.00 )
ISRG' s 10-Year Shiller P/E Range
Min: 31.02   Max: 790
Current: 44

31.02
790
Current Ratio 3.31
ISRG's Current Ratio is ranked higher than
76% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. ISRG: 3.31 )
ISRG' s 10-Year Current Ratio Range
Min: 2.07   Max: 7.43
Current: 3.31

2.07
7.43
Quick Ratio 2.90
ISRG's Quick Ratio is ranked higher than
79% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. ISRG: 2.90 )
ISRG' s 10-Year Quick Ratio Range
Min: 1.72   Max: 7.07
Current: 2.9

1.72
7.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 42.50
ISRG's Price/Net Cash is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ISRG: 42.50 )
ISRG' s 10-Year Price/Net Cash Range
Min: 2.88   Max: 333.4
Current: 42.5

2.88
333.4
Price/Net Current Asset Value 25.60
ISRG's Price/Net Current Asset Value is ranked higher than
78% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ISRG: 25.60 )
ISRG' s 10-Year Price/Net Current Asset Value Range
Min: 2.43   Max: 35.43
Current: 25.6

2.43
35.43
Price/Tangible Book 6.90
ISRG's Price/Tangible Book is ranked higher than
69% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. ISRG: 6.90 )
ISRG' s 10-Year Price/Tangible Book Range
Min: 2.05   Max: 16.35
Current: 6.9

2.05
16.35
Price/DCF (Projected) 1.80
ISRG's Price/DCF (Projected) is ranked higher than
90% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ISRG: 1.80 )
ISRG' s 10-Year Price/DCF (Projected) Range
Min: 1.46   Max: 14.73
Current: 1.8

1.46
14.73
Price/Median PS Value 0.90
ISRG's Price/Median PS Value is ranked higher than
84% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. ISRG: 0.90 )
ISRG' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 2.09
Current: 0.9

0.31
2.09
Price/Peter Lynch Fair Value 3.70
ISRG's Price/Peter Lynch Fair Value is ranked higher than
95% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ISRG: 3.70 )
ISRG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.81   Max: 3.95
Current: 3.7

0.81
3.95
Price/Graham Number 3.60
ISRG's Price/Graham Number is ranked higher than
80% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ISRG: 3.60 )
ISRG' s 10-Year Price/Graham Number Range
Min: 1.76   Max: 7.88
Current: 3.6

1.76
7.88
Earnings Yield (Greenblatt) 3.20
ISRG's Earnings Yield (Greenblatt) is ranked higher than
78% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ISRG: 3.20 )
ISRG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 9.8
Current: 3.2

0.4
9.8
Forward Rate of Return (Yacktman) 15.23
ISRG's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. ISRG: 15.23 )
ISRG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.1   Max: 141.9
Current: 15.23

-1.1
141.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:IUI1.Germany,
Intuitive Surgical, Inc., is a Delaware corporation founded in 1995. The Company designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories. A da Vinci Surgical System consists of a surgeon's console, a patient-side cart and a high performance vision system. The da Vinci Surgical System translates a surgeon's natural hand movements, which are performed on instrument controls at a console, into corresponding micro-movements of instruments positioned inside the patient through small incisions, or ports. The da Vinci Surgical System is designed to provide its operating surgeons with intuitive control, range of motion, fine tissue manipulation capability and Three Dimensional, High-Definition vision while simultaneously allowing surgeons to work through the small ports enabled by MIS procedures. The Company has commercialized three generations of da Vinci Surgical System - the da Vinci Si Surgical System, the da Vinci S Surgical System and the standard da Vinci Surgical System. The Company manufactures da Vinci Surgical Systems at its facility in Sunnyvale, California. It manufactures instruments at its Sunnyvale facility and Mexicali, Mexico facility. The Company faces competition from several companies that are developing new approaches and products for the MIS market. The Company's products and operations are subject to extensive and rigorous regulation by the FDA.
» More Articles for ISRG

Headlines

Articles On GuruFocus.com
S&P 500 Finishes Above 2,000 Aug 27 2014 
Manning & Napier's Top 5 Second Quarter Stock Buys Jul 23 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows May 08 2014 
Baron Funds Comments on Intuitive Surgical May 05 2014 
Morning Coffee: Widely Held Guru Stocks Near 52-Week Lows May 01 2014 
5 Depressed Companies Ready for a Rebound - Worthy of a December Buy! Dec 13 2013 
Viking Global Investors’ Impact Selling Nov 29 2013 
Baron Funds Comments on Intuitive Surgical Inc. Nov 21 2013 
John Burbank's Top 10 Third Quarter Buys Nov 14 2013 
Baron Funds Comments on Intuitive Surgical Inc. Nov 06 2013 


More From Other Websites
Cody Willard: 3 key growth trends to invest in Dec 17 2014
Intuitive Surgical Reports New Employee Option Grants for December 2014 Dec 11 2014
Intuitive Surgical Reports New Employee Option Grants for December 2014 Dec 11 2014
Insider Trading Alert - RPTP, TEAR And ISRG Traded By Insiders Nov 26 2014
Bank Of America Impressed By Intuitive Surgical Following Congress Nov 25 2014
Top Medical Centers Awarded da Vinci(R) Technology Grants for Robotic Surgery Simulation Practice Nov 13 2014
Intuitive Surgical Reports New Employee Option Grants for November 2014 Nov 11 2014
Intuitive Surgical Reports New Employee Option Grants for November 2014 Nov 11 2014
Impact of US-China trade deal Nov 11 2014
INTUITIVE SURGICAL INC Financials Oct 30 2014
Medical Equipment Stocks Rise; Idexx Clears Buy Point Oct 28 2014
Bonds hold losses after weak 2-year note auction Oct 28 2014
Can Fat-Freezer Zeltiq Aesthetics Heat Up Profits? Oct 24 2014
INTUITIVE SURGICAL INC Files SEC form 10-Q, Quarterly Report Oct 23 2014
As earnings season heats up, stocks close on the lows… Oct 22 2014
How WIll Intuitive Surgical (ISRG) Stock React to Its Earnings Beat Today? Oct 22 2014
Intuitive Surgical (ISRG) Earnings Report: Q3 2014 Conference Call Transcript Oct 22 2014
Intuitive Surgical Q3 Earnings Fall but Beat Estimates Oct 22 2014
UPDATE: BTIG Upgrades Intuitive Surgical Oct 22 2014
Intuitive Surgical upgraded by Northland Capital Oct 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK